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ABSTRACT 
β-lactamases are increasing worldwide speedily by creating problem to currently available UTI therapies and hence 
there is an urgent need of research to find the effective therapy. In the present study we propose to develop drug 
formulation for the reversal of drug resistance in MDR E.cancerogenus MAB-1 by using bioenhancer property of 
isolated different phytochemicals (lead compounds). β-lactamase enzyme of E.cancerogenus MAB-1 was produced 
and purified up to 92.5 fold, by using Ion-Exchange chromatography(DEAE-Cellulose -52) techniques with 80.23 
U/mg of specific activity. Iso-electric focusing and Sodium Dodecyl Sulfate –Polyacrylamide gel electrophoresis 
(SDS-PAGE) study revealed enzyme with PI value 8.5 with Molecular weight ~6.5 KDa. Threonine (9.27 ppm) and 
Serine (3.94 ppm) were detected in highest quantity when analyzed by GC-MS technique.  Organic and Water 
extracts of selected plants were investigated for GC-MS, IR, NMR analysis for the isolation of pure lead compounds 
i.e. Theobromine, Myricetin, Gallic acid, Ellagic acid, Kaempferol and Genistein. In vitro Enterobacter 
cancerogenus MAB-1 β-lactamase inhibition by Dug-phytochemical combinations was studied by Checker board 
and Time-Kill curve at their ½ to 1/32 MIC values. The Theobromine+ Cefaclor synergy inhibited β-lactamases by 
91%, Myricetin +Cefaclore (90%), Genistein+Cefaclore (92%), Genistein + Cefotaxime(90%), Genistein+Penicillin 
(91%) , Ellagic acid+Cefaclor (87%), Kaempferol+Ceftriaxone(87%), Kaempferol+Cefaclor (90%) and Clavulanic 
Acid (96%) Competitively, Gallic acid+Cefotaxime (92%) Non-Competitively. Thus the resulting data would be 
helpful to pick up the most effective and suitable combination therapy for further research in the area of drug 
development against UTI caused by E.cancerogenus MAB-1 or any member of Enterobacteriaceae family. 
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     INTRODUCTION
Community or Nosocomial Urinary Tract Infections (UTI) are increasing worldwide speedily by creating problem to 
currently available β-lactam antibiotic therapies. The clinical efficacy of many existing antibiotics are being threatened 
by the emergence of multidrug-resistant pathogens [1]. The saga of Enterobacter as a nosocomial pathogen is closely 
linked to the logarithmic increase in the use of extended-spectrum Cephalosporin in the 1980’s. The clinically isolated 
novel multidrug resistant strain Enterobacter cancerogenus MAB-1  (GenBank: JX827386) belongs to the 
family  Enterobacteriaceae which possess TEM,SHV, BLA type β-lactamases is our study of interest [2]. Bacterial 
resistance to β-lactam antibiotics is often associated with the production of β-lactamase (Penicillin amidohydrolase; 
EC 3.5.2.6), which hydrolyses the β-lactam ring (4 atom cyclic amide rings,  6 APA- 6-Aminopenicillanic acid)  at C4 
position. This reaction gives rise to biologically inactive products and represents the most widespread mechanism of 
resistance.  Thus it is an urgent need of research to find the effective therapeutic options to treat / manage the UTI.   
 
Synergy is the basis of using combination antimicrobial therapy. Now a days there are considerable studies pertaining 
to the role of antimicrobial synergy in the treatment of serious infections caused by both Gram-positive and Gram 
negative organisms. In search of more effective stratergies, elaborating new antimicrobial agents and developing 
combination therapies to improve the efficacy and to reduce the toxicity of various drugs the synergistic combination 
will be helpful in treating infections caused by ESBL producing bacteria. It has been documented that some cellular 
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targets of bacterial resistance to antimicrobial drugs are consisting of active antibiotic efflux from the cell interior and 
prevention of entry of compound in to the cell, altering permeability of the cell membrane to reduce drug uptake, 
inactivating antimicrobial agents such as hydrolyzing their β-lactam ring and changing bacteria’s cellular targets by 
mutation of target sites [3].  One specific hypothesis to combat multidrug resistant bacteria is to increase the uptake 
of antibacterial agents into the bacterial cells by interfering with cellular permeability barriers of cell membrane and 
cell wall structures of microorganisms. Here we hypothesized that phytochemicals can improve the entrance of 
antibiotics through bacterial membrane to target their sites and bypass bacterial resistance. Secondary metabolites 
from medicinal herbs and dietary plants possess a range of bioactivities like - antibacterial, antifungal, antiviral, 
antimutagenic and anti-inflammatory activities. Moreover, extensive clinical evidence has shown that 
chemoprevention by phenolic phytochemicals is an inexpensive, readily applicable approach in the chemotherapy and 
management [4]. It is speculated that due to herb-antibiotic synergy the inhibition of efflux pump and bacterial 
resistance mechanism could be altered [5]. Though exact mechanism of these non antibiotic drugs are not well 
understood but these compounds can modulate ion channel activity and make microbial adaptability difficult [6,7]. 
The rich chemical diversity in plants as a potential source of antibiotic resistance modifying compounds are yet to be 
adequately explored. Definitely herbal medicines will not replace antimicrobials but helps to revert bacterial 
resistance. Thus the synergistic effect from the association of antibiotics with phytochemicals against multi-drug 
resistant bacteria may emerge as new approach for the treatment of infectious diseases [8]. Totarol, Epicatechin, 
Berberin, Reserpine etc are some resistance modifiers derived from plants [9]. Modulators are compounds that 
potentiate antibiotic activity against resistant strains.  
 
Thus the present study we propose to develop drug formulation for the drug resistance reversal in MDR 
E.cancerogenus MAB-1 by using biopotentiators (bioenhancers) properties of isolated six different phytochemicals 
or lead compounds ((Theobromine, Myricetin, Ellagic acid, Gallic acid. Kaempferol and Genistein) with seven 
different β-lactam antibioitcs (Cefotaxime, Ceftazidime, Ceftriaxone, Cefaclor, Amoxicillin, Ampicillin and 
Penicillin). All antibiotics under investigation have earlier been reported as β-lactam drugs and may have different 
mechanisms of action (have different targets).  
 
MATERIALS AND METHODS 
Production of β-lactamases from Enterobacter cancerogenus MAB-1  
 For optimum production of β-lactamases, Enterobacter cancerogenus MAB-1 strain was cultivated aerobically in 2-
lit batch culture of optimized Muller-Hinton broth media with 0.1% Nitrocefin. The initial pH of media was adjusted 
to 7.5. A 2.5 % (v/v) of inoculum was added in total broth culture and incubated at 370C temperature for 24 h on rotary 
shaker (120rpm/min).At the end of fermentation; bacterial cells were harvested by centrifugation at 8,000 rpm for 20 
min. The resulting cell pellets were resuspended in 0.1M phosphate buffer (pH 7) and disrupted by lysis buffer 
containing 05 mg/ml lysozyme and incubated at 370C for 30 min on shaker [10]. The cell debris was removed by 
centrifugation at 10,000rpm for 20 min at 40C and cell –free supernatant was designed as crude β-lactamase and used 
for further purification process. All the preperations were carried out at 40C temperature. 
 
β-lactamase crypticity 
β-lactamase crypticity was defined as the ratio of the activity of the disrupted cell to that of the intact cells.The cells 
were disrupted by treatment with 1% toluene for at least 30 min. 
                       β-lactamase crypticity =   Activity of disrupted cells 
                                                                   Activity of intact cells 
 
Enzyme purification 
Purification of the enzyme was carried out according to the standard method with some modifications [11]. The crude 
β-lactamase was fractionated with addition of ammonium sulfate to obtain saturations (30, 40, 50, 60 and 70% w/v). 
The precipitate was collected by centrifugation at 10,000 rpm/20min at 40C and dissolved in 0.05M potassium 
phosphate buffer (pH 7.5), followed by dialysis (10 KDa molecular weight cut off) against same buffer of low molarity 
(0.01m M) for overnight at 40C temperature. The dialyze was passed through a DEAE (Diethylaminoethyl)-cellulose 
52 column pre-equilibrated with 0.05 M phosphate buffer (pH 7.5).The enzyme elution was performed with a linear 
gradient of 0.1 to 0.5 M NaCl. The active enzyme fractions were pooled, concentrated with ammonium sulfate 
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treatment and dialyzed. The dialyzed was again passed through DEAE-cellulose 52 column with same buffer. 
Fractions in milliliter were collected per minute and estimated for protein concentration as well as β-lactamase activity. 
 
Protein estimation 
Protein concentration was determined by the standard method using Bovine Serum albumin (BSA) as the standard 
[12]. 
 
Assay of β-lactamase  
β-lactamase activity was determined Spectrophotometrically [13] with some modifications. The rate of breakdown of 
substrate (Nitrocefin) in the presence of β-lactamase was determined by measuring the rate of change of ultraviolet 
light associated with β-lactam ring. The standard mixture contains total volume of 3 ml reaction mixture containing 
1.9ml of 51.6 μg/ml of Substrate (Nitrocefin) in 0.05 M Phosphate buffer (pH 7), 1 ml 0.1.M Phosphate buffer (pH 
7). The reaction was started by addition of 0.1ml enzyme solution in a total volume of 2.9 ml. Enzyme concentration 
at which the rate of reaction complete in 5 min was found to be the most convenient and the change in absorbance at 
386 nm wavelength was measured  over first 2 min. One unit of activity of the enzyme was defined as micromoles of 
substrate destroyed per minute per milliliter of enzyme at 370C at pH 7 at 386 nm.  
Enzyme Activity = X/1.03 × 0.3× v μmole destroyed per min per milliliter of enzyme 
                            where: X= is the ΔOD/minute observed, 0.3 is the number of micromoles of Nitocefin present and 
v is the factor for adjusting enzyme volume to 1ml. 
Iso-electric focusing 
Isoelectric point (PI) value of β-lactamase from E.cancerogenus MAB-1 was determined by Iso-electric focusing by 
using 2-D PAGE with ready IPG strips (Ampholine pH gradient: 3-10) using the Bio-Rad PROTEAN IEF cell. The 
focusing was carried out for three days i.e. Day 1 : Rehydration of IPG strips were done with Enterobacter 
cancerogenus MAB-1 β-lactamase for 12 h. Day 2: Enzyme focusing and Day 3: Destaining for 120 min. β-lactamase 
focusing bands were detected by overlaying the gel with solution of Commassie Brilliant blue. The gel was observed 
for development of blue bands. The coordinate of active bands were recorded. 
 
Molecular mass determination and Purity checking 
The relative molecular mass and purity of the β-lactamase was determined by Sodium Dodecyl-Sulfate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) on 10% polyacrylamide gel using standard protein markers:  
Myosin (205KDa), Phosphorylase b (97.4KDa), Bovin serum albumin (66KDa), Ovalbumin (43KDa),Carbonic 
unhydrase (29KDa), Soyabean Trypsin inhibitor (20.1KDa), Lysozyme (14.3KDa), Apoprotin (6.5KDa) and Insulin 
(3.5KDa). After electrophoresis the gel was stained with Commassie Brilliant blue stain for 1 h, followed by destaining 
for 30 min in distilled water and photographed. 
 
Bioactivity guided fractionation for isolation of lead compounds  
Fresh plants of Acacia catechu (Khair), Hemidesmus indicus (Anantmul) , Santalum album (Chandan) , Acorus 
calamus (Vekhand) , Vetivera zinanoides (Ushirwala) , Justicia adhatoda (Adulsa ) , Withania somnifera 
(Ashwagandha), Tinospora cordifolia (Gulwel) , Hibiscus rosa-sinensis  (Jashwandpushp), Asparagus racemousus 
(Shatawari) were collected (January - December 2012) randomly ,extracted by solvent extraction method and  
employed for GC-MS analysis for confirmation of probable phytochemicals [14].  Preliminary TLC was done of each 
extract for determining the column solvent system. Selected each extract was mixed with 20 g of Silica gel (100-200 
mesh) to become a slurry. The slurry was loaded onto the wet packed column and continuously eluted with the mobile 
phase or solvents starting with n-Hexane, Petroleum ether, benzene, chloroform, ethyl acetate and methanol by 
increasing or decreasing polarity individually. Each sample yielded 20 fractions of 25 ml aliquots of eluent which was 
collected by observing the distance travelled by the sample down to the column. In addition, bands of the each fraction 
formed on TLC were also monitored. The fractions showing TLC mobility and band formation were pooled and the 
solvent evaporated under a steady air current at room temperature. Fractions which did not give single sharp band on 
the TLC plates were re-fractionated using same silica gel column in different solvent system.  
 
Assaying fractions for antibacterial testing 
All fractions of all extracts were assayed against test strain Enterobacter cancerogenus MAB-1 for potent 
antimicrobial activity [15]. Fraction no F3,F5,F7,F4 of Hemidesmus indicus extract,F9,F3,F1 of Acacia catechu 
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extract,F11,F5,F8,F10 of Santalum album extract,F4 of Vetivera zinanoides extract,F15,F17 of Acorus calamus 
extract,F5 of both Justicia adhatoda extract and  Withania somnifera extract were tested for potential antimicrobial 
activity against the test strain and hence these fractions from each plant extract was combined according to their Rf 
value in to six main fractions and named F1,F2,F3,F4, F5 and F6 respectively. These six fractions employed for IR, 
NMR anlaysis for the identification of lead bioactive compounds as per standard procedure. 
 
Determination of Minimum Inhibitory Concentration (MIC)  
Minimum Inhibitory Concentration (MIC) of isolated six phytochemicals and Standard β-lactam antibiotics for 
Enterobacter cancerogenus MAB-1 was determined by Tube Dilution method [16]. Varying concentrations of 
phytochemicals and Antibiotics ranging from 240-0.01 μg/ml were prepared in 3 ml nutrient broth, 0.5Mac Farland 
turbidity adjusted Enterobacter cancerogenus MAB-1culture was added into each test tube. Test tubes were incubated 
at 370C for 24 h and examined for turbidity. After incubation, tube containing least concentration of phytochemicals 
showing no visible sign of growth was considered as the minimum inhibitory concentration (MIC). 
 
Synergistic interaction of isolated Phytochemicals with Standard Antibiotics (The Checkerboard analysis)  
To get MIC of the combination i.e. all seven standard β-lactam Antibiotics and Theobromine, Myricetin, Ellagic acid, 
Galiic acid, Kaempferol and Genistein against Enterobacter cancerogenus MAB-1, the cells were inoculated in MHB 
and incubated under following different combinations viz: Cefaclor + Gallic acid, Theobromine, Ellagic acid, 
Kaempferol, Myricetin, Genistein of 240-0.001ug/ ml concentration; Cefotaxime + Gallic acid, Theobromine, Ellagic 
acid, Kaempferol, Myricetin, Genistein of 240-0.001ug/ ml concentration; Ceftazidime + Gallic acid, Theobromine, 
Ellagic acid, Kaempferol, Myricetin, Genistein of 240-0.001ug ml-1 concentration; Ceftriaxone + Gallic acid, 
Theobromine, Ellagic acid, Kaempferol, Myricetin; Genistein of 240-0.001ug/ ml concentration; Ampicillin+ Gallic 
acid, Theobromine, Ellagic acid, Kaempferol, Myricetin, Genistein of 240-0.001ug/ ml concentration; Amoxicillin+ 
Gallic acid, Theobromine, Ellagic acid, Kaempferol, Myricetin, Genistein of 240-0.001ug/ ml concentration and 
Penicillin+ Gallic acid, Theobromine, Ellagic acid, Kaempferol, Myricetin, Genistein of 240-0.001ug/ ml 
concentration. To eliminate other random factors all assays were carried out in triplicates to determine accurate MIC 
of antibiotic and Phytochemicals in combination and individually. 
 
Synergistic interactions between Third Generation Cephalosporin antibiotics viz. Cephotaxime, Ceftazidime, 
Ceftriaxone, Cefaclor, Amoxicillin, Ampicillin and Penicillin with Theobromine, Myricetin, Ellagic acid, Gallic acid, 
Kaempferol and Genistein, were studied using Broth Dilution Checkerboard method. In this method, 0.5 Mac Farland 
turbidity adjusted inoculum of E.cancerogenus MAB-1 strain was inoculated in to 3 ml of sterile nutrient broth. 
Phytochemicals and antibiotic combinations at concentration of 1/32 × MIC to 2 × MIC (combined above cited MIC) 
were added into tubes of culture. The fractional inhibitory concentration was derived from the lowest concentration 
of antibiotics and phytochemical combination showing no visible growth of the test organism after an incubation of 
24 h.  FIC was calculated by using the formula, 
 
FIC index = (MIC of antibiotic in combination/MIC of antibiotic alone) + (MIC of phytochemical in combination 
/MIC of phytochemical alone).   
 
The results were interpretated as synergistic - if the FIC indices were < 0.5; Additive - if FIC indices were between 
0.5- 4 and Antagonistic - if the FIC indices were > 4 [17]. 
 
Time –Kill curve 
Time-Kill synergy assay [18] was carried out to find out the enhanced antibacterial effect of Phytochemicals and 
Antibiotic combination against Test strain. Tubes containing 10 ml of MHB broth with above mentioned antibiotics 
and Phytochemicals (at concentration of 1/2,1/4,1/8,1/16 and 1/32 times of their MIC) alone and in combinations and 
one tube without antibiotics were inoculated with 100 μl of actively growing E.cancerogenus MAB-1 culture adjusted 
to yield a final inoculums of 105 cells / ml.  All above cited combinations were incubated at 370C. The negative control 
was maintained with Phytochemicals and antibiotics individually. Growth rates of bacterial species were assessed at 
every ½ hr interval by measuring absorbance (OD) at 600 nm (Shimadzu, Japan). 
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Post Antibiotic Effect (PAE) 
The post antibiotic effect was tested in Phytochemical +Antibiotic synergistic combinations only. 20 ml of 1:20 diluted 
overnight grown and 0.5 Mac Ferland turbidity adjusted culture of E.cancerogenus MAB-1 in MH broth was 
inoculated for 2 h at 370C with antibiotics and Phytochemicals (at a concentration of 1/2,1/4,1/8,1/16 and 1/32 times 
of their MIC) alone and in combinations. In order to remove the antibiotics and phytochemicals, the exposed bacteria 
was washed twice with the phosphate buffered saline (pH 7) by centrifugation for 7,000 rpm. Control was handled 
similarly.The pellets were resuspended in 20 ml of MHB followed by incubation at 370C and samples (1 ml) were 
obtained at 1/2 h of exposure to antibiotics, Phytochemicals and their combinations for corrections that were made to 
ensure that all the cultures would start with the same bacterial count. Samples were removed at time 0 (immediately 
after washing and correction ) and then hourly up to 12 h and the OD values were determined ( reflecting the bacterial 
growth).The OD values were converted in to CFU (bacterial growth) by using a standard curve which was constructed 
relating the bacterial count to the OD. The Post Antibiotic Effect (PAE) is defined according to - 
                                                            PAE = T- C 
 
Where T is the time required for the viable counts of the exposed bacteria to increase by 1 log 10 of above the counts 
observed immediately after washing and C is the corresponding time for the sample unexposed to antibiotic and 
phytochemical alone and in combination (control) [19]. 
 
Inhibition study of E.cancerogenus MAB-1 β-lactamases 
Inhibitory activity of each Antibiotic, Phytochemical and Antibiotic+ Phytochemical combination was determined 
with slight modifications [20]. The assay mixture contains various concentrations of inhibitors i. e. Antibiotic, 
Phytochemicals alone, Antibiotic + Phytochemical in combination and Standard inhibitor Clavulanic acid in 
concentration range of 0.01μm-35 μm. The assay mixture was incubated with 0.5 ml of purified β-lactamases 
separately for different time period from 0.5-120 min. In case of Phytochemical + Antibiotic combination the 
synergistic combination of Time –Kill study formulation was used for inhibition. About 0.1 ml sample was removed 
periodically and 1ml nitrocefin was added to the reaction mixture to record the absorbance.The blank was prepared 
without enzyme solution. The test was prepared in triplicate. β-lactamase activity was expressed as percent inhibition 
of β-lactamase as- 
                                       % inhibition=100×(C-r) /c 
Where; C=Activity in control incubated without inhibitor;  
             r= Remaining activity in samples incubated with inhibitor and 
                                              
                                         IC50=I(Vi)/(Vo-Vi) 
Where;   I=Concentration  of inhibitor which gives rate of Vi 
        Vo=Rate of control lacking inhibitor 
         Vi=rate of sample with inhibitor  
Lineweaver-Burk plot of Vmax (is maximal velocity) and Km (is concentration at 50% Vmax) was calculated.The IC50 
value i.e. mM concentration of inhibitor is necessary for 50% inhibition were determined from the above mentioned 
formula. 
 
RESULTS AND DISCUSSION 
β-lactamase crypticity is the ratio of activity of disrupted cells/ intact cells of isolate E. cancerogenus MAB-1. 
Nitrocefin exhibited highest crypticity i.e.52 whereas other substrates Cefaclor (32), Ceftriaxone (42), Amoxicillin 
(36), Amikacin (47), Chloramphenicol (30) and Ciprofloxacin (40) revealed moderate crypticity. Cefalexin (50) alone 
exhibited crypticity similar to Nitrocefin. Remaining all substrates revealed very less crypticity. Thus according to 
crypticity data it can be concluded that Nitrocefin is the ideal one for the maximum β-lactamase production in 
disrupted as well as intact cells of Enterobacter cancerogenus MAB-1 rather than any other substrates tested (Table 
1). The purified β-lactamase from Enterobacter cancerogenus MAB-1 revealed 92.5 purification fold which is similar 
with other microbial β-lactamases [Table 2 & Fig.1]. The enzyme showed optimum activity at pH 7 and 300C 
temperature as well as broad stability over a wide range of pH (7-7.5) and temperature (200C-300C) [Fig. 1 &2 
Supplementary Data].The enzyme is ~6.5KDa having PI value 8.5[ Fig.2 &3].  
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About ten different plants viz. Acacia catechu (Khair), Hemidesmus indicus (Anantmul) , Santalum album (Chandan) 
, Acorus calamus (Vekhand) , Vetivera zinanoides (Ushirwala) , Justicia adhatoda (Adulsa ) , Withania somnifera 
(Ashwagandha), Tinospora cordifolia (Gulwel) , Hibiscus rosa-sinensis  (Jashwandpushp), Asparagus racemosus 
(Shatawari) were collected for isolation of bioactive compounds to treat Enterobacter cancerogenus MAB-1 caused 
UTI infection. The plants were from different families i.e. Apocynaceae, Santalaceae, Acoraceae, Poaceae, 
Acanthaceae, Solanaceae, Menispermaceae, Malvaceae and Liliaceae. Most of the plants of these families are well 
known for their antimicrobial activity against common as well as drug resistant pathogens but yet no report is present 
about these plants regarding UTI infection. The bark of Acacia catechu and Santalum album, roost of Hemidesmus 
indicus and Asparagus racemousus, whereas Rhizome of Acorus calamus. Grass of Vetivera zinanoides and flowers 
of Hibiscus rosa-sinensis and shrub of Justicia adhatoda, Withania somnifera, Tinospora cordifolia were used. 
 
Our main objective was to find out active lead compound to kill MDR E.cancerogenus MAB-1 so all extracts were 
employed for GC-MS analysis for probable determination of the phytochemicals in each plant extract. GC-MS 
analysis revealed large number of phytochemicals but Gallic acid, Ellagic acid, Threobromine, Genistein, Myricetin 
were the prominent peak [Table 1.,supplimentary data]. For identification of phytochemicals all fractions were 
subjected for antimicrobial tests and only 6 fractions revealed promising AST [Fig.4] against E.cancerogenus MAB-
1. F1: Fraction of Hemidesmus indicus (15±0.22 mm) ,F2: Fraction of Acacia catechu (17±0.04 mm), F3&F4: Fraction 
of Santalum album(21±0.86 mm ; 13±0.94mm ) ,F5: Fraction of Acorus calamus (11±0.00 mm ),F6: Fraction of 
Justicia adhatoda (10±0.07mm). After IR and NMR analysis [Table 3] the fractions were identified as F1: Ellagic 
acid, F2: Myricetin, F3: Theobromine, F4: Gallic acid, F5: Kaempferol and F6: Genistein etc.  Results of antimicrobial 
assay revealed that acetone and ethanol extract of plant exhibited broad spectrum activity against tested isolates as 
compared to aqueous extract. Susceptibility of pathogens varied to solvent and aqueous extract. This indicates the 
involvement of more than one active principles of biological significance [21]. The traditional healers use primarily 
water as the solvent, but we observed that plant extracts prepared in ethanol and acetone as solvents provided more 
consistent antimicrobial activity, as also reported earlier [22,23]. These observations can be rationalized in terms of 
the polarity of the compounds being extracted by each solvent and, in addition to their intrinsic bioactivity, by their 
ability to dissolve or diffuse in the different media used in the assay. In the present study negligible inhibitory activity 
with aqueous extract was observed in most of the plants which may be due to loss of some active compounds during 
extraction process of the sample or there may be lack of solubility of active constituents in aqueous solution [24]. 
Alternatively, active compounds may be present in insufficient quantities in the crude extracts to show activity with 
the dose levels employed [25]. 
 
Thus the six lead phytochemicals having promising antimicrobial activity against MDR E.cancerogenus MAB-1 as a 
resistance modulators were isolated and identified. The isolated lead compounds and β-lactam antibiotics were 
subjected for determination of Minimum Inhibitroy Concentration (Table.4) as per standard procedure. The results 
revealed MIC values for Theobromine 240 μg/ml, Myricetin >10 μg/ml, Ellagic acid 1 μg/ml, Gallic acid 240 μg/ml 
and Kaempferol 1 μg/ml whereas in case of antibiotics Ceftriaxone 0.1 μg/ml, Ceftazidime 0.1 μg/ml, Cefotaxime 
0.032 μg/ml, Cefaclor 480 μg/ml, Amoxicillin 128 μg/ml, Ampicillin 0.1 μg/ml and Penicillin 240 μg/ml MIC against 
the test strain E.cancerogenus MAB-1. MIC determination of test compounds against test strain is the most essential 
criteria for calculating FIC index as well as formulation therapy.     
 
The combination effects of β-lactam drugs and phytochemicals are depicted (Table.5). The results showed that 
combinations of Genistein + Penicillin, Theobromine + Ceftazidime, Theobromine + Cefotaxime, Myricetin + 
Cefaclor, Ellagic acid + Cefaclor, Ellagic acid+ Ceftazidime, Gallic acid + Cefotaxime, Kaempferol + Ceftriaxone, 
Kaempferol + Cefaclor , Theobromine + Cefaclor revealed synergistic mode of interactions for E.cancerogenus MAB-
1under investigation. Whereas other combinations were additive in nature but only one combination i.e. Gallic acid + 
Ceftriaxone revealed Antagonastic effect against the test strain. (Table.5). It is noteworthy, that only one antibiotic-
phytochemical combination showed antagonism. The FIC indices of the combinations Genistein+ Penicillin, 
Theobromine + Ceftazidime, Theobromine + Cefotaxime, Myricetin + Cefaclor, Ellagic acid + Cefaclor, Ellagic acid+ 
Ceftazidime, Gallic acid + Cefotaxime, Kaempferol +Ceftriaxone, Kaempferol + Cefaclor , Theobromine + Cefaclor 
were ranged from 0.10 – 0.5. The growth inhibitory properties of all the test compounds and additive combinations 
assayed over 20 h periods at sub-inhibitory concentrations. Moreover, the synergistic combinations were found to 
inhibit the test strain growth at similar concentrations. 
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Time-kill assays are illustrated for the most potent synergistic combinations (Genistein+Penicillin, 
Theobromine+Ceftazidime,Theobromine+Cefotaxime,Myricetin+Cefaclor,Ellagic acid + Cefaclor, Ellagic acid+ 
Ceftazidime, Gallic acid+Cefotaxime, Kaempferol +Ceftriaxone, Kaempferol + Cefaclor , Theobromine + Cefaclor) 
on E.cancerogenus MAB-1(Fig.5: a-f). The net reduction in colony count was seen consistently (throughout 24 h) at 
(1/2th + 1/32th) x MIC for the identified synergistic drug-phytochemical combinations. Any single active agent alone 
at 1/2th x MIC did not show significant inhibition of the tested isolates. The rate of killing was higher at 6 h with 
maximum reduction in the colony count at 24 h. The ½ MIC of Theobromine+1/4 MIC of Cefaclor significantly 
decrease bacterial count between 2.5 h with maximum reduction in the growth baseline by 6 – 7 log10 CFU/ml. 
However, when ¼ MIC Gallic Acid + ½ MIC Cefotaxime combined a reduction of 7 log10 decrease in viable count 
occurred at 11 h. ½ MIC EA+1/32MIC  Ceftazidime decreased viable count by 7 log 10 at 6 h; ¼ MIC Myr+ ¼  MIC 
Cefaclor decreased viable count by 7 log 10 at 9 h , ½MIC GEN+ ½MIC Penicillin decreased viable count by 7 log 
10 at 5 h and combination of ¼ MIC KEM+1/2 MIC Cefaclor decreased viable count by 7 log 10 at 6.5 h( Fig.5: a-f). 
A strong synergy observed between the Genistein + Penicillin, Theobromine + Ceftazidime, Theobromine + 
Cefotaxime, Myricetin + Cefaclor, Ellagic acid + Cefaclor, Ellagic acid + Ceftazidime, Gallic acid + Cefotaxime, 
Kaempferol + Ceftriaxone, Kaempferol + Cefaclor , Theobromine + Cefaclor is a significant finding demonstrating 
the therapeutic potentials of these phytochemicals. The concentrations relative to MIC may have a major role to play 
in the outcomes of the combinational experiments.  
 
Combined antibiotic therapy has been shown to delay the emergence of bacterial resistance and may also produce 
desirable synergistic effects in the treatment of bacterial infection. Drug synergism between antibiotics and bioactive 
phytochemicals is a novel concept and could be beneficial (Synergistic or Additive interaction) or deleterious or Toxic 
outcome. The antimicrobial and resistance modifying potentials of naturally occurring compounds have been reported 
in studies [26]. This would suggest that the synergy with antibiotics observed could be attributable to some 
compounds, like polyphenols which exert their antibacterial action through membrane perturbations. This perturbation 
of the cell membrane coupled with the action of β-lactams on the transpeptidation of the cell membrane could lead to 
an enhanced antimicrobial effect of the combination [27]. These mechanisms of action can be obtained by the 
combination of antibiotics with extract at a sub-inhibitory concentration applied directly to the culture medium 
[28].This strategy is called “Herbal shotgun” or “synergistic” “multieffect targeting” and refers to the utilization of 
plants and drugs in an approach using more or multi phytochemical combinations, which affect not only a single target 
but various targets. The action involves different therapeutic components collaborate in a synergistic combinations 
between natural or synthetic products with antibiotics. Sometimes the use of single antibiotic does not produce the 
desired or the effective inhibitory effects and to overcome this, combination of drugs often exercise their synergistic 
effect which surpasses their individual performance. 
 
Bacterial efflux pumps are responsible for a significant level of resistance to antibiotics in pathogenic bacteria. Some 
plant derived components have been observed to enhance the activity of antimicrobial compounds by inhibiting MDR 
efflux system in bacteria [29]. 5’-methoxy hydanocarpin is an example of an inhibitor of the nor A efflux pump of 
S.aureus isolated from Berneries fremontii [30]. It is likely that the Theobromine,Myricetin, Ellagic 
acid,Genistein,Kaempferol and Gallic acid could contain potential efflux pump inhibitors. Such compounds are likely 
to be broad spectrum efflux inhibitors as synergistic effect was observed on MDR E.cancerogenus MAB-1 as well as 
in combination with cell wall inhibiting and protein synthesis inhibiting antibiotics. 
 
Antibiotics could interfere with bacterial cell wall synthesis, increase bacterial membrane permeability and /or inhibit 
bacterial protein synthesis at the 30S subunit of ribosome; therefore the different modes of action of the phytochemical 
with the antibiotics may be an important factor in the enhanced bactericidal efficacy observed when used in 
combination. 
 
The antimicrobial resistance modifying potentials of naturally occurring flavonoids and polyphenolic compounds have 
been reported in other studies such as [26]. It has also been shown that some plant derived components can improve 
the in vitro activity of some peptidoglycan inhibiting antibiotics by directly attacking the same site (i.e.peptidoglycan) 
in the cell wall. Here we recommended the evaluation of the exact Drug-Phytochemical ratio at which the interaction 
was maximum between the phytochemical and antimicrobial drug. A wider study with increase in the number of drugs, 
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increase in number of clinical isolates especially MDR is necessary to establish the mode of action against the 
E.cancerogenus MAB-1.  
 
Post-Antibiotic Effect (PAE) (Table.6) is a well-established pharmacodynamic parameter that reflects an arrested 
bacterial growth, following the removal of the active antibacterial agent from the growth medium [31]. The duration 
of the PAE is mainly influenced by the bacterial species, and the nature of the antibacterial drug and its concentration. 
Environmental factors such as temperature, pH, O2, growth medium, the kind of body fluid etc also affect PAE. 
Addition of Genistein + Penicillin, Theobromine + Ceftazidime, Theobromine + Cefotaxime, Myricetin + Cefaclor, 
Ellagic acid + Cefaclor, Ellagic acid+ Ceftazidime, Gallic acid + Cefotaxime, Kaempferol + Ceftriaxone, Kaempferol 
+ Cefaclor , Theobromine + Cefaclor seems to prolong the post antibiotic effect of all above combined β-lactam 
antibiotics. Interestingly Theobromine, Myricetin, Ellagic acid, Amoxicillin, Kaempferol, Genistein or Cefaclor, 
Ceftazidime, Cefotaxime, Ceftriaxone, Penicillin, Ampicillin, Gallic acid when used alone does not depress the growth 
of the microorganism after they were removed. 
 
The kinetic behavior of the compounds that inhibit the β-lactamase activity was studied [Table.7]. The type of 
inhibition was determined by Lineweaver—Burk and Dixon plots. The reciprocals of the velocity of the reaction was 
plotted against the substrate concentrations of the inhibitors in the Lineweaver-Burk plot and Dixon plot respectively 
for the inhibitor constant(Ki).Percentage inhibition was calculated from the standard formula. Phytchemical + β-
lactam Antibiotic combination inhibited β-lacatamase in vitro in a dose dependent manner with minimum inhibitory 
activity [Table.7]. 
  
The combinations of Theobromine+Cefaclore, Theobromine + Ceftazidime, Theobromine + Cefotaxime, Myricetin + 
Amoxicillin, Myricetin + Cefaclore, Genistein + Cefaclor, Genistein + Ceftazidime, Genistein + Cefotaxime, 
Genistein + Penicillin, Gallic acid + Ceftriaxone, Gallic acid + Cefotaxime, Ellagic acid + Cefaclor, Ellagic acid + 
Ceftazidime,Kaempferol + Cefaclor, Kaempferol+Amoxicillin, Kaempferol+Ceftriaxone, Kaempferol+Penicillin 
displayed significant concentration dependent β-lactamase inhibition with respect to control from 79-90% [Table.7]. 
These 10 combinations posses the most potent inhibitory activity with IC50 values ranging from 0.95 - 3.1, than the 
positive control Clavulanic acid (0.115). The Kaempferol +Ampicillin, Kaempferol+ Ceftazidime, Kaempferol + 
Cefotaxime, Ellagic acid + Ceftriaxone, Gallic Acid + Amoxicillin, Gallic Acid + Penicillin, Gallic Acid + Ampicillin, 
Myricetin + Ampicillin, Myricetin + Ceftazidime, Theobromine + Ceftriaxone, Theobromine + Ampicillin 
combinations revealed moderate β-lactamase inhibitory activity in the range of (60-75%). Kinetic studies of 
Phytochemical and Antibiotic alone exhibited non-competitive and competitive inhibition respectively. Percentage 
inhibition activity of the Phytochemicals and Antibiotics alone revealed 8-89%, while standard showed 96% of 
inhibition at their highest concentration with minimum substrate concentration. The activity of these compounds 
greatly dependednt upon the nature of the substuents in the Phytochemical + Antibiotic . Upon close inspection of the 
inhibitory activity exerted by these compounds, a biological profile on the Structure – Activity relationship could be 
deduced as follows- The position of the hydroxyl (-OH) is probably responsible for such inhibition. The 
Phytochemical+ Antibiotic combinations that are non-competitive have OH in positions C3', C4', C5 and C7, while 
those are competitive have a hydroxyl in positions C4 ', C5 and C7. The hydroxyl at C3 'seems to be able to modify 
the interaction of combination with the β-lactamase and thus the type of inhibition. The Genistein, Cefaclor and 
Cefotaxime had low effect on the enzyme activity. This could be due to the absence of hydroxyl groups on the C5 and 
C7. Ellagic Acid and Gallic acid had inhibitory effect on β-lactamase, suggesting that the structure C6-C3-C6 is 
important for this inhibition. 
 
Thus the combinations i.e. Theobromine + Cefaclore, Theobromine + Ceftazidime, Theobromine + Cefotaxime, 
Myricetin + Amoxicillin, Myricetin + Cefaclore, Genistein + Cefaclor, Genistein + Ceftazidime, Genistein + 
Cefotaxime, Genistein + Penicillin, Gallic acid + Ceftriaxone, Gallic acid + Cefotaxime, Ellagic acid + Cefaclor, 
Ellagic acid + Ceftazidime, Kaempferol + Cefaclor, Kaempferol+Amoxicillin, Kaempferol+Ceftriaxone and 
Kaempferol + Penicillin with their proper formulation could be a lead compounds for anti-UTI drug discovery.  
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CONCLUSION 
The present study clearly highlights the low toxic potential of phytochemicals as antibacterial compounds and suggest 
the possibility of use of the above mentioned synergistic drug-herb combinations for combating infections caused by 
this pathogen. The drug-herb network presented in this study shows the level of interactions between various classes 
of antibiotics and phytochemicals and provides a baseline to identify the potential mechanism of action of these 
potential phytochemicals. Moreover, phytochemicals are reported to have the capability of increasing the 
susceptibility of the pathogen to various drugs and also reduce the toxicity of the drugs when used in combination. 
The synergistic effect may be due to certain complex formation which becomes more effective in the inhibition of a 
particular species of microorganisms either by inhibiting the cell wall synthesis or by causing its lysis or death. Finally, 
the experimental findings encourage further studies such as in vivo animal experiments to validate these interesting 
observations before clinical test. This study probably suggests the possibility of concurrent use of these antimicrobial 
drugs and phytochemicals in combination for treating Urinary Tract infections caused by E.cancerogenus MAB-1. 
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Tables: 
Table 1.    β-lactamase Crypticity 
Sr.No. Drugs (Con.100 um) Ratio of activity of disrupted cells/Intact cells of 
isolate E. cancerogenus MAB-1 
 
1 Imipenem 18 
2 Cefoxitin 21 
3 Nitrocefin 57 
4 Cefaclore 32 
5 Ceftazidime 27 
6 Cefotaxime 24 
7 Ceftriaxone 42 
8 Ampicillin 25 
9 Amoxycillin 36 
10 Penicillin 29 
11 Amikacin 47 
12 Aztreonam 22 
13 Cefpirome 18 
14 Cefalexin 50 
15 Norfloxacin 30 
16 Chloramphenicol 40 
17 Kanamycin 20 
18 Tetracycline 15 
19 Piperacilline 17 
20 Ciprofloxacine 12 
 
Table 2. Purification of β- lactamases from E. cancerogenus MAB-1 
Purification step β-lactamases 
activity 
(U/min/ml) 
Total protein 
(mg/ml) 
Specific activity 
(U/mg) 
Yield (%) Purifiaction  fold 
Crude extract 2,260 62 36.45 100 1 
Dialysis 
(Ammonium 
Sulphate) 
 
3,170 
 
35 
 
58.02 
 
88 
 
1.8 
DEAE-
Cellulose-52 
         85 11 80.23 16.4 92.5 
 
Table 3. Antibiogram Pattern of Fractions on Test Strain Enterobacter cancerogenus MAB-1 
Test Strain Fractions (Zone Diameter in mm) 
 F1 F2 F3 F4 F5 F6 
Enterobacter 
cancerogenus 
MAB-1 
15±0.22 mm 17±0.04 mm 21±0.86 
mm 
13±0.94 
mm 
11±0.00 mm 10±0.07 
mm 
Data given are mean of 3 replicates ±S.D. P<0.05;   F1: Fraction of Hemidesmus indicus ,F2: Fraction of Acacia 
catechu ,F3&F4: Fraction of Santalum album ,F5: Fraction of Acorus calamus ,F6: Fraction of Justicia adhatoda. 
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Table 4. Determination of Minimum Inhibitory Concentration (MIC) of isolated lead compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. In vitro Checkerboard FIC Index (Interpretation) of all Antibiotics + Phytochemicals combinations 
against E.cancerogenus MAB-1 
Sr.No. Antibiotics + Phytochemicals combination Checker board FIC Index 
(Interpretation) 
1  Theobromine+Cefaclor  0.5 (S)  
2  Theobromine+Ceftazidime  0.25(S)  
3  Theobromine+Cefotaxime  0.5 (S)  
4  Theobromine+Ceftriaxone  1   (A)  
5  Theobromine+Ampicillin  2.1 (A)  
6  Theobromine+Amoxicillin  0.7 (A)  
7  Theobromine+Penicillin  3    (A)  
1  Myricetin+Penicillin  3(A)  
2  Myricetin+Ampicillin  2.5(A)  
3  Myricetin+Ceftazidime  1(A)  
4  Myricetin+Ceftriaxone  2.1(A)  
5  Myricetin+Amoxicillin  0.99(A)  
6  Myricetin+Cefotaxime  0.75(A)  
7  Myricetin+Cefaclor  0.12(S)  
1  Ellagic acid+Amoxicillin  3.3(A)  
2  Ellagic acid+Penicillin  2.4(A)  
3  Ellagic acid+Ceftriaxone  1.8(A)  
4  Ellagic acid+Cefotaxime  0.92(A)  
5  Ellagic acid+Ampicillin  0.67(A)  
6  Ellagic acid+Cefaclor  0.37(S)  
7  Ellagic acid+ Ceftazidime  0.10(S)  
1  Gallic acid+Ceftriaxone  4.5(ANT)  
2  Gallic acid+ Ampicillin  3.8(A)  
3  Gallic acid+Penicillin  3.1(A)  
4  Gallic acid+Amoxicillin  2.5(A)  
5  Gallic acid+Cefaclor  1.7(A)  
6  Gallic acid+Ceftazidime  0.73(A)  
7  Gallic acid+Cefotaxime  0.5(S)  
1  Kaempferol +Cefotaxime  3.4(A)  
2  Kaempferol+ Ceftazidime  2.2(A)  
Test compounds MIC (μg/ml) 
Theobromine, 240 
Myricetin, >10 
Ellagic acid, 1 
Gallic acid. 240 
Kaempferol 1 
Genistein 32 
Ceftriaxone 0.1 
Ceftazidime 0.1 
Cefotaxime 0.032 
Cefaclor 480 
Amoxicillin 128 
Ampicillin 0.1 
Penicillin 240 
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3  Kaempferol+Ampicillin  1.9(A)  
4  Kaempferol+Penicillin  1(A)  
5  Kaempferol+Amoxicillin  1(A)  
6  Kaempferol+Ceftriaxone  0.5(S)  
7  Kaempferol+Cefaclor  0.25(S)  
1  Genistein+ Cefaclor  3.1(A)  
2  Genistein+Ceftazidime  2.5(A)  
3  Genistein+Cefotaxime  2(A)  
4  Genistein+Ceftriaxone  1.6(A)  
5  Genistein+Ampicillin  0.97(A)  
6  Genistein+Amoxicillin  0.73(A)  
7  Genistein+Penicillin  0.13(S)  
S= Synergy; A= Additive; ANT= Antagonastic 
 
Table 6. Post antibiotic effect of Antibiotic and Phytochemicals alone and in combination against 
E.cancerogenus MAB-1 
     Sr.No.                        Treatment      Post antibiotic effect   (PAE) 
                         (in h) 
1  Theobromine 0.5 
2  Myricetin 0 
3  Ellagic acid 0 
4  Gallic acid 0.5 
5 Kaempferol 1 
6 Genistein 0 
7 Cefaclor 0 
8 Ceftazidime 0 
9 Cefotaxime 0.5 
10 Ceftriaxone 0 
11 Penicillin 0 
12 Ampicillin 0.5 
13 Amoxicillin 0 
14 Theobromine+Cefaclor  7 
15 Theobromine+Ceftazidime  4.5 
16 Theobromine+Cefotaxime  5 
17 Myricetin+Cefaclor  5 
18 Ellagic acid+Cefaclor  3.5 
19 Ellagic acid+ Ceftazidime  4 
20 Gallic acid+Cefotaxime  6 
21 Kaempferol+Ceftriaxone  2.5 
22 Kaempferol+Cefaclor  5.6 
23 Genistein+Penicillin  3 
 
Table 7.  In vitro β-lactamase inhibitory activity of Phytochemicals, Antibiotics and Antibiotic + Phytochemical 
combination 
Sr.
No. 
Compounds Km Ki(mM) IC 50 % 
Inhibition 
Inhibition type 
1 Theobromine 
 
0.07 0.76 0.61 89% Non-Competitive 
2        Myricetin 0.078 0.62 
 
0.43 58% Non-Competitive 
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3 Ellagic acid 0.09 0.48 
 
0.50 74% Non-Competitive 
4 Gallic acid 0.07 1.15 
 
0.69 63% Non-Competitive 
5 Kaempferol 0.18 2.32 
 
0.54 77% Non-Competitive 
6 Genistein 0.5 0.60 
 
0.51 41% Non-Competitive 
7 Cefaclore 0.45 1.4 
 
0.73 27% Competitive 
8 Ceftazidime 0.41 2.30 
 
1.5 13% Competitive 
9 Cefotaxime 0.55 2.1 
 
1.65 8% Competitive 
10 Ceftriaxone 0.55 1.7 
 
1 21% Competitive 
11 Ampicillin 0.48 0.85 
 
2.9 19% Competitive 
12 Amoxicillin 0.32 0.01 
 
0.39 19% Competitive 
13 Penicillin 0.39 0.42 3.7 39% Competitive 
14 Theobromine + Cefaclore 
 
0.12 
 
0.33 
 
0.15 
 
91% 
 
Non-Competitive 
 
15 Theobromine + 
Ceftazidime 
0.09 
 
0.25 
 
0.22 
 
86% 
 
Non-Competitive 
 
16 Theobromine + 
Cefotaxime 
 
0.15 
 
0.45 
 
0.90 
 
87% 
 
Non-Competitive 
 
17 Theobromine+Ceftriaxone 
 
0.36 
 
0.05 
 
0.18 
 
75% 
 
Non-Competitive 
 
18 Theobromine+Ampicillin 
 
0.2 
 
0.43 
 
0.21 
 
62% 
 
Non-Competitive 
 
19 Theobromine+Amoxicillin 0.23 
 
0.65 
 
0.33 
 
50% 
 
Competitive 
 
20 Theobromine +Penicillin 
 
0.05 
 
2.1 
 
0.10 
 
43% 
 
Non-Competitive 
 
21 Myricetin +Penicillin 
 
0.003 
 
1.6 
 
1.5 
 
54% 
 
Competitive 
 
22 Myricetin+Ampicillin 
 
0.23 
 
0.9 
 
0.17 
 
67% 
 
Competitive 
 
23 Myricetin+Ceftazidime 
 
0.1 
 
1.1 
 
0.17 
 
73% 
 
Non-Competitive 
 
24 Myricetin+Ceftriaxone 
 
0.06 
 
0.36 
 
1.3 
 
78% 
 
Competitive 
 
25 Myricetin+Amoxicillin 
 
0.034 
 
0.07 
 
21 
 
83% 
 
Non-Competitive 
 
26 Myricetin+Cefotaxime 
 
0.4 
 
0.73 
 
4.8 
 
79% 
 
Non-Competitive 
 
27 Myricetin+Cefaclore 
 
0.23 
 
0.24 
 
3.7 
 
90% 
 
Competitive 
 
28 Genistein+Cefaclore 
 
0.12 
 
0.53 
 
1.01 
 
92% 
 
Competitive 
 
 
[Bhande* et al., 5(7): July, 2016]  ISSN: 2277-9655 
IC™ Value: 3.00                                                                                                         Impact Factor: 4.116 
http: // www.ijesrt.com                 © International Journal of Engineering Sciences & Research Technology 
 [266] 
29 Genistein+ Ceftazidime 
 
0.34 
 
0.17 
 
1.97 
 
89% 
 
Competitive 
 
30 Genistein+Cefotaxime 
 
0.67 
 
0.5 
 
0.39 
 
90% 
 
Competitive 
 
31 Genistein+Ceftriaxone 
 
0.78 
 
0.16 0.83 86% Non-Competitive 
 
32 Genistein+Ampicillin 0.09 
 
1.3 
 
0.45 
 
86% 
 
Non-Competitive 
 
33 Genistein+Amoxicillin 
 
0.07 
 
0.21 
 
2.3 
 
70% 
 
Competitive 
 
34 Genistein+Penicillin 
 
0.03 
 
0.36 1.65 91% Competitive 
35 Gallic acid+Ceftriaxone 
 
0.012 
 
0.83 
 
0.43 
 
80% 
 
Competitive 
 
36 Gallic Acid+Ampicillin 
 
0.34 
 
0.39 
 
0.15 
 
77% 
 
Non-Competitive 
 
37 Gallic Acid+Penicillin 
 
0.65 
 
0.06 
 
3.7 
 
71% 
 
Non-Competitive 
 
38 Gallic Acid+Amoxicillin 
 
0.78 
 
0.48 3.4 
 
65% 
 
Competitive 
 
39 Gallic Acid+Cefaclore 
 
0.98 
 
0.09 
 
4.7 
 
53% 
 
Competitive 
 
40 Gallic Acid+Ceftazidime 
 
0.23 
 
0.37 
 
1.5 
 
40% 
 
Non-Competitive 
 
41 Gallic acid+Cefotaxime 0.45 
 
1.32 
 
0.77 
 
92% 
 
Non-Competitive 
 
42 Ellagic acid+Amoxicillin 0.76 1.22 2.3 41% Competitive 
 
43 Ellagic acid+Penicillin 0.81 0.76 0.9 57% Competitive 
 
44 Ellagic acid+Ceftriaxone 0.54 0.81 1.3 62% Non-Competitive 
 
45 Ellagic acid+Cefotaxime 0.76 0.13 3.9 81% Non-Competitive 
 
46 Ellagic acid+Ampicillin 0.53 0.4 0.04 87% Competitive 
 
47 Ellagic acid+Cefaclor 0.04 0.50 0.27 87% Competitive 
 
48 Ellagic acid + Ceftazidime 0.7 0.18 1.6 88% Non-Competitive 
 
49 Kaempferol +Cefotaxime 0.38 0.63 0.13 63% Competitive 
 
50 Kaempferol+ Ceftazidime 0.75 0.27 0.09 70% Non-Competitive 
 
51 Kaempferol+Ampicillin 0.62 0.24 0.47 77% Competitive 
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52 Kaempferol+Penicillin 0.07 2.32 0.15 80% Non-Competitive 
 
53 Kaempferol+Amoxicillin 0.35 0.76 1.9 81% Competitive 
 
54 Kaempferol+Ceftriaxone 0.1 0.35 0.24 87% Competitive 
 
55 Kaempferol+Cefaclor 0.24 0.45 0.50 90% Competitive 
 
56 Clavulanic Acid 
 
0.33 
 
0.067 
 
0.115 
 
96% 
 
Competitive 
 
 
        
Figures: 
 
Fig.1. Elution profile (DEAE-Cellulose-52 ) of β-lactamase from E.cancerogenus MAB-1 
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Fig 2.Determination of Isoelectric point (PI)  of  β-lactamase from E.cancerogenus MAB-1 by Isoelectric 
Focusing 
 
 
Fig.3. SDS- PAGE of purified β-lactamase from E.cancerogenus MAB-1 on 10% polyacrylamide gel. 
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Fig.4. Antibiogram Pattern of Fractions on Test Strain Enterobacter cancerogenus MAB-1 
 
F1: Fraction of Hemidesmus indicus ,F2: Fraction of Acacia catechu ,F3&F4: Fraction of Santalum album ,F5: 
Fraction of Acorus calamus ,F6: Fraction of Justicia adhatoda. 
 
Fig. 5. Time-kill curve of E.cancerogenus MAB-1 
Fig. 5 (a) Time-kill curve of E.cancerogenus MAB-1 with Theobromine + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
 
 
Fig. 5 (b) Time-kill curve of E.cancerogenus MAB-1 with Myricetin + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
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Fig. 5(c) Time-kill curve of E.cancerogenus MAB-1 with Ellagic acid + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
 
 
Fig. 5 (d) Time-kill curve of E.cancerogenus MAB-1 with Gallic acid + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
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Fig. 5 (e) Time-kill curve of E.cancerogenus MAB-1 with Kaempferol + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
 
 
Fig. 5 (f) Time-kill curve of E.cancerogenus MAB-1 with Genistein + Ceftriaxone, Ceftazidime, Cefotaxime, 
Cefaclor, Amoxicillin, Ampicillin, Penicillin 
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Fig.1.  Effect of pH on purified β-lactamase activity 
 
 
Fig.1 (a). Effect of pH on stability of purified β-lactamase 
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Fig.2. Effect of Temperature on purified β-lactamase activity. 
 
Fig.2 b) Effect of Temperature on stability of purified β-lactamase activity 
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Table 1.  IR,NMR analysis for structure elucidation of lead compounds 
• Gallic acid  (Mol.Wt. 170.12 ) 
IR (KBr):3363(-OH) cm-1, 3286(Carboxylic -OH) cm-1, 3063(Ar-H) cm-1, 1705(>C=O) cm-1. 1H-NMR (DMSO): 
δ12.0( s, 1H, acidic OH), δ9.0 ( s, 2H, Ar-H), δ3.4 (s, 3H, OH ). 
• Ellagic acid (Mol.Wt. 302.19 ) 
IR (KBr):3471(-OH) cm-1, 3155(Ar-H) cm-1, 1720(-OC=O) cm-1. 1H-NMR (DMSO): δ3.4 (m, 4H, -OH), δ7.7(s, 
2H, Ar-H). 
• Theobromine (Mol.Wt. 180 ) 
IR (KBr):3155(-NH) cm-1, 3024(-CH, assym) cm-1, 2823(-CH symm) cm-1, 1689(amide), 1550(C=N) cm-1. 1H-
NMR (DMSO): δ11.1(s, 1H, NH), δ8.0(s, 1H, -CH), δ3.9(s, 3H, -CH3), δ3.1(s, 3H, -CH3). 
• Kaempferol (Mol.Wt. 286.24) 
IR (KBr):3420(bs, -OH) cm-1, 3100(Ar-H) cm-1, 3000(=CH), 1720(>C=O) cm-1, 1135(-O-C-O) cm-1. 1H-NMR 
(DMSO): δ12(s, 1H, OH), δ7.5(s, 2H, Ar-H), δ7.2 (m, 4H, Ar-H), δ3.5 (s, 2H, OH), δ3.0(s, 1H, OH). 
• Genistein (Mol.Wt.  270) 
IR (KBr):3500(bs, OH) cm-1, 3160(Ar-H) cm-1, 2950(=CH) cm-1, 1675(α, β-unsaturated ketone) cm-1, 1140(-O-C-
O) cm-1.  1H-NMR (DMSO): δ7.4(s, 2H, Ar-H), δ7.1 (q, 4H, Ar-H), δ6.5(s, 1H,=CH), δ3.8(s, 3H, OH). 
• Myricetin (Mol.Wt 318.24.) 
IR (KBr):3451(bs, OH) cm-1, 3100(Ar-H) cm-1, 1669(>C=O) cm-1, 1138(-O-C-O) cm-1. 1H-NMR (DMSO): 
δ12.0(s, 1H, OH), δ7.9(s, 2H, Ar-H), δ7.5(s, 2H, Ar-H), δ3.9(s, 5H, OH). 
 
 
 
